Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parmax PharmaBOM:540359 42 3-Year ROIIC % is 0.00 as of Mar. 2026. GuruFocus rates BOM:540359 with a GF Score™ of 42/100 and a GF Value™ of ₹40.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 944 Drug Manufacturers companies, Parmax Pharma ranks worse than 105932.1% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Parmax Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Parmax Pharma's 3-Year ROIIC % or its related term are showing as below:
BOM:540359's 3-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.565 * Ranked among companies with meaningful 3-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Parmax Pharma 3-Year ROIIC % Related Terms
Parmax Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Parmax Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's 3-Year ROIIC % falls into.
Parmax Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -33.103249 (Mar. 2026) - 0 (Mar. 2023) )
/
( 197.14 (Mar. 2026) - 124.896 (Mar. 2023) )
=
/
72.244
=
0.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Parmax Pharma (BOM:540359) has a 3-Year ROIIC % of 0.00 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Parmax Pharma and its competitors. Over the past decade, Parmax Pharma's 3-Year ROIIC % has ranged from 0.33 to 245.56. According to the industry distribution chart, Parmax Pharma ranks #999999 out of 944 companies in the Drug Manufacturers industry.
Is Parmax Pharma's 3-Year ROIIC % too high?
Parmax Pharma's current 3-Year ROIIC % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 245.56. Based on the distribution chart, Parmax Pharma ranks #999999 out of 944 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Parmax Pharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #999999 out of 944 companies for 3-Year ROIIC %. This places Parmax Pharma in the lower half of its industry. The industry median 3-Year ROIIC % is 3.57. Historically, Parmax Pharma's own 3-Year ROIIC % has ranged from 0.33 to 245.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.57, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹40.79, compared to a current price of ₹131.15 — trading 221.5% above its estimated fair value. The current 3-Year ROIIC % is 0.00. Parmax Pharma's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current 3-Year ROIIC % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹131.15 is trading 221.5% above its estimated GF Value™ of ₹40.79.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
3-Year ROIIC %: 0.00
GF Value™: ₹40.79 vs. price of ₹131.15 (221.5% above fair value)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
